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Introduction {#sec1}
============

The pathogenesis of chronic myeloid leukemia (CML) is centered on the *BCR*/*ABL* fusion gene and the subsequent expression of the constitutively active BCR/ABL tyrosine kinase ([@bib53]). The introduction of imatinib, the prototype of tyrosine kinase inhibitors (TKi) capable to target BCR/ABL, opened a new era in CML treatment, allowing up to 90% of chronic-phase patients to achieve deep molecular response and prolonged survival ([@bib17]). However, TKi do not show the same efficacy in the treatment of patients in accelerated phase or blast crisis. In addition, following discontinuation of TKi, most patients relapse ([@bib43]), likely due to the insensitivity to TKi of leukemia stem cells (LSCs) ([@bib25], [@bib22], [@bib24]), the cell subset that sustains minimal residual disease ([@bib21]). Thus, the identification of druggable targets different from BCR/ABL is a crucial goal to aim at CML eradication.

The extracellular signal-regulated kinase 5 (\[ERK5\], also referred to as big mitogen-activated kinase 1 \[BMK1\]) belongs to the mitogen-activated protein kinase family ([@bib38]), and is emerging as a promising target for cancer treatment, also thanks to the availability of small-molecule inhibitors of ERK5 or its upstream activator MEK5 ([@bib66], [@bib58], [@bib54], [@bib40]). Cytokines, growth factors ([@bib51]), and stress factors are upstream activators of MEK5, which activates ERK5 through phosphorylation at Thr218/Tyr220 ([@bib16], [@bib45]). The MEK5/ERK5 pathway is involved in the pathogenesis of different types of cancer ([@bib44], [@bib20], [@bib52], [@bib3], [@bib59]), and ERK5 has been reported to contribute to the oncogenic potential of BCR/ABL ([@bib2]).

Low oxygen is a critical environmental condition ensuring the maintenance of hematopoietic stem cells (HSCs) ([@bib9], [@bib14], [@bib46], [@bib19], [@bib32]), 0.1% O~2~ being a physiological occurrence in bone marrow (BM) ([@bib8]) that allows HSC cycling ([@bib28], [@bib27]). Incubation at 0.1% O~2~ suppressed BCR/ABL protein and allowed to select, from the BCR/ABL-dependent CML cell bulk, CML cells which can survive and cycle independently of BCR/ABL signaling. These cells retain progenitor/stem cell potential and result refractory to TKi ([@bib22], [@bib23], [@bib24], [@bib5]).

In this study, we investigated the role of the ERK5 pathway in the maintenance of CML LSCs in view of its possible therapeutic inhibition.

Results {#sec2}
=======

The ERK5 Pathway Is Active and Required for Optimal Growth in CML Cells {#sec2.1}
-----------------------------------------------------------------------

The expression of ERK5 protein in myeloid leukemia cell lines, including K562 CML cells, has been reported previously ([@bib2], [@bib61]). We show here that in the K562, KCL22, and LAMA84 CML cell lines ERK5 was phosphorylated at the activation loop residues Thr218/Tyr220, so that an ERK5 band with reduced electrophoretic mobility was detectable ([Figure 1](#fig1){ref-type="fig"}A). The constitutive activity of ERK5 was confirmed by *in vitro* kinase assay ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B) in KCL22 and K562 cells, widely used as CML models and therefore chosen for further experiments *in vitro*. Importantly, ERK5 was expressed and phosphorylated at Thr218/Tyr220 in bone marrow mononuclear cells (BMMCs) from CML patients ([Figure 1](#fig1){ref-type="fig"}B).Figure 1ERK5 Expression and Effects of ERK5 Pathway Inhibition in CML Cells(A and B) ERK5 expression in human CML cell lines and primary cells. Immunoblotting of total cell lysates of routinely cultured (A) CML cell lines or (B) BMMCs from CML patients. (A) Slower-migrating phosphorylated form of ERK5 (arrow). GAPDH or tubulin are loading controls. Representative images from three (A) or two (B) independent experiments.(C--E) Effects of MEK5/ERK5 inhibitors on KCL22 and K562 cell number and cell-cycle phase distribution in low oxygen. Cells were incubated in 0.1% O~2~ and treated with DMSO (Vehicle) or the indicated inhibitors from time 0 to the indicated times. (C) Viable cell count; values are means ± SD of data from three independent experiments; ^∗^p \< 0.05; ^∗∗^p \< 0.01 versus vehicle at the same time point. (D) Cell-cycle phase distribution; representative plots from three independent experiments, averaged (means ± SEM) in the table; ^∗^p \< 0.05, ^∗∗^p \< 0.01 versus vehicle. (E) Immunoblotting of total cell lysates of CML cell lines; tubulin is a loading control; representative images from four independent experiments.(F and G) Effects of MEK5/ERK5 inhibitors on primary CML cells. Patient-derived cells were incubated in normoxia and treated with DMSO (Vehicle), 10 μM XMD8-92 (XMD), or 10 μM BIX02189 (BIX) from time 0 to day 3. (F) Data are means ± SD of the percentages of apoptotic cells (n = 3); ^∗^p \< 0.05 versus vehicle. (G) Data are means ± SD of data (n = 3) showing cell-cycle phase distribution. Differences between drug- and vehicle-treated samples were not statistically significant.

We then evaluated the role of ERK5 in CML cell growth, using the ERK5 inhibitor XMD8-92 ([@bib66]) and the MEK5 inhibitor BIX02189 ([@bib58]). Either drug reduced the number of viable cells in culture in a concentration-dependent manner ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). On the basis of previous studies ([@bib52], [@bib56], [@bib34]) and in order to reduce possible off-target effects, we performed all subsequent experiments using an XMD8-92 and BIX02189 concentration (10 μM) lower than the half maximal inhibitory concentration (IC~50~) values determined in KCL22 and K562 cells incubated in normoxia or low oxygen (0.1% O~2~; [Figure S1](#mmc1){ref-type="supplementary-material"}E). This inhibitor concentration was able to suppress the constitutive ERK5 kinase activity ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B) and to reduce significantly KCL22 and K562 cell growth ([Figure S1](#mmc1){ref-type="supplementary-material"}F). This reduction was lower than that induced by imatinib ([Figure S1](#mmc1){ref-type="supplementary-material"}F) used at a concentration (1 μM) around 2-fold the IC~50~ reported previously ([@bib5], [@bib50], [@bib4]). The lack of effect of 10 μM XMD8-92 on the proliferation of K562 cells where ERK5 expression had been suppressed by small hairpin RNA (shRNA) led to exclude possible off-target effects of XMD8-92 at this concentration ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H) ([@bib40]).

Subsequent experiments directed to study the role of the ERK5 pathway in the maintenance of CML progenitor/stem cell potential were performed incubating cells in low oxygen. In low oxygen, similarly to that observed in normoxia ([Figure S1](#mmc1){ref-type="supplementary-material"}F), a 3-day treatment with XMD8-92 or BIX02189 reduced the number of viable KCL22 and K562 cells ([Figure 1](#fig1){ref-type="fig"}C). The effect of XMD8-92 or BIX02189 in reducing cell number was apparently due to a block of cell cycle in G0/G1 phase ([Figure 1](#fig1){ref-type="fig"}D) rather than to the induction of apoptosis. Indeed, while imatinib, as expected, induced apoptosis, XMD8-92 or BIX02189 did not ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). The G0/G1 block was consistent with the increased expression of p27 ([Figure 1](#fig1){ref-type="fig"}E), a critical negative regulator of cell-cycle progression. We obtained similar results incubating cells in normoxia ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2G). With respect to primary CML BMMCs, XMD8-92 and BIX02189 induced apoptosis significantly ([Figure 1](#fig1){ref-type="fig"}F), while showing appreciable but not significant G0/G1 cell accumulation at the expense of the S phase ([Figure 1](#fig1){ref-type="fig"}G).

Inhibition of the ERK5 Pathway Reduces Progenitor Cell Potential of CML Cell Lines in Low Oxygen {#sec2.2}
------------------------------------------------------------------------------------------------

To identify a druggable target to achieve LSC suppression, we tested the effects of MEK5/ERK5 inhibitors on the maintenance of CML progenitor cell potential using CML cell lines as a first approach ([Figure 2](#fig2){ref-type="fig"}). KCL22 and K562 cells were treated with XMD8-92 or BIX02189 from time 0 of incubation in low oxygen (LC1) and transferred on day 7 to drug-free cultures (LC2) incubated in normoxia ([Figure 2](#fig2){ref-type="fig"}A), to evaluate the progenitor cell potential of LC1 cells by the culture repopulation ability (CRA) assay ([@bib22], [@bib24]). ERK5 pathway inhibition markedly reduced (BIX02189) or suppressed (XMD8-92) the progenitor cell potential of KCL22 and K562 cells, while imatinib showed negligible effects as reported previously ([@bib22], [@bib24]). Conversely, the appropriateness of ERK5 targeting in CML cells incubated in low oxygen was supported by the fact that ERK5 protein was maintained, although partially reduced with respect to time 0 ([Figure S3](#mmc1){ref-type="supplementary-material"}A). The reduction of ERK5 protein level following BCR/ABL protein suppression is consistent with a previous report showing that ERK5 protein level depends on BCR/ABL only in part ([@bib2]). This partial dependence was confirmed by showing that ERK5 expression level in low oxygen remained relatively high upon imatinib treatment despite BCR/ABL inhibition, which was witnessed by the markedly reduced phosphorylation of the BCR/ABL target CRKL ([Figure S3](#mmc1){ref-type="supplementary-material"}B).Figure 2Effects of ERK5 Pathway Inhibition on the Progenitor Cell Potential of CML Cell Lines(A) Effects of MEK5/ERK5 inhibitors on CRA. Kinetics of repopulation of drug-free normoxic secondary cultures (LC2) established with KCL22 or K562 cells rescued from primary cultures (LC1) incubated in 0.1% O~2~ and treated for 7 days with DMSO (Vehicle) or the indicated inhibitors. Values are means ± SD of three independent experiments. Differences between drug- and vehicle-treated cultures were significant (p ≤ 0.01) from day 21 (KCL22) or day 17 (K562) on for BIX02189, and from day 14 (KCL22) or day 10 (K562) on for XMD8-92.(B and C) Effects of ERK5 genetic inhibition in K562 cells on cell number and CRA. (B) Cells transduced with (inset) non-targeting control (shNT) or two different ERK5-targeting shRNA (shERK5-1, shERK5-2) were incubated in 0.1% O~2~ and viable cells counted at the indicated times of LC1. ^∗^p ≤ 0.05 versus shNT at the same time point. (C) LC2 repopulation by cells from day 7 LC1 shown in (B). Values are means ± SD of three independent experiments. Differences between shERK5-1 or shERK5-2 with respect to the shNT control were significant (p \< 0.05) from day 24 on.

To confirm that the above-described effects of drugs were due to ERK5 pathway inhibition, we performed ERK5 knockdown using shRNA. Genetic inhibition of ERK5 ([Figure 2](#fig2){ref-type="fig"}B, inset) halved the number of viable K562 cells in low oxygen ([Figure 2](#fig2){ref-type="fig"}B) and suppressed CRA ([Figure 2](#fig2){ref-type="fig"}C). Taken together, these results indicated that the ERK5 pathway was important for the maintenance of progenitor cell potential of CML cell lines.

Pharmacological Inhibition of the ERK5 Pathway Reduces the Number and Colony Formation Ability of Primary CML Cells as well as the Number of CML Cells *In Vivo* {#sec2.3}
----------------------------------------------------------------------------------------------------------------------------------------------------------------

We next evaluated the effects of MEK5/ERK5 inhibitors on primary CML cells. The effects of ERK5 (ten patients) or MEK5 (four patients) inhibition on the number of viable BMMCs in low oxygen is shown in [Figures 3](#fig3){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A. XMD8-92 and BIX02189 determined a reduction of viable BMMCs ranging from negligible (nos. 4, 9, 17, and 25) to marked (nos. 10, 16, 28, and 29) ([Figure S4](#mmc1){ref-type="supplementary-material"}A). When the data obtained for the single patients were pooled together, it emerged that, in keeping with that observed for CML cell lines, the detrimental effect of XMD8-92 or BIX02189 on the overall cell viability was significant, although not exceeding that of TKi ([Figure 3](#fig3){ref-type="fig"}A). Furthermore, XMD8-92 and BIX02189, similarly to TKi, robustly reduced the colony formation ability (CFA) of BMMCs from CML patients ([Figure 3](#fig3){ref-type="fig"}B). It is worth noting that in the same experiments 3 μM XMD8-92 was also effective.Figure 3Effects of Pharmacological Inhibition of the ERK5 Pathway *In Vivo* and on Primary CML and Normal CD34+ Cells(A) Effects of MEK5/ERK5 inhibitors on the number of viable primary CML cells. CML BMMCs were incubated at 0.1% O~2~ and treated with DMSO (Vehicle) or the indicated inhibitors (XMD, XMD8-92; BIX, BIX02189; IM, imatinib; DAS, dasatinib) and viable cells counted at day 3. Values are means ± SD. See [Figure S4](#mmc1){ref-type="supplementary-material"}A for single patient data. The number of patients for each group is indicated (vehicle group: n = 10). ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01.(B) Effects of MEK5/ERK5 inhibitors on the CFA of primary CML cells. CML BMMCs were treated with DMSO (Vehicle) or inhibitors from time 0 and colonies scored after 7 days. Colony formation efficiency (CFE) values are means ± SD of data from single experiments performed in duplicate; ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01.(C) Effects of XMD8-92 *in* *vivo*. CML mice (mice/group: n = 6) were treated twice daily with XMD8-92 (50 mg/kg) or placebo and euthanized after 1 additional day. Number of GFP+ (leukemic) or GFP− (non-leukemic) myeloid (Gr-1+) BM cells; data are means ± SD (left graph). Total number of viable BM cells; data are means ± SD (right graph). ^∗^p \< 0.05; ns, not significant.(D) Effects of MEK5/ERK5 inhibitors on the number of viable primary CML and normal CD34+ cells. CD34+-enriched CML BMMCs or healthy donor PBMCs were treated with DMSO (Vehicle) or inhibitors at the indicated concentrations and incubated in 0.1% O~2~ and viable cells counted at day 2. Values are means ± SD of data normalized for the respective vehicle-treated control. The number of patients/healthy donors is indicated; ^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001; ns, not significant.(E) Effects of MEK5/ERK5 inhibitors on CFA of primary CML or normal CD34+ cells. CD34+-enriched CML BMMCs or healthy donor PBMCs were treated with DMSO (Vehicle) or inhibitors at the indicated concentrations from time 0 and colonies scored after 7 days. CFE values are means ± SD of data normalized for the respective vehicle-treated control. The number of patients/healthy donors is indicated (see [Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D for data of single experiments); ^∗^p ≤ 0.05; ^∗∗∗^p ≤ 0.001; ns, not significant.(F and G) Effects of MEK5/ERK5 inhibitors on the differentiation potential of primary CML or normal CD34+ cells. In the same experiments shown in (E), differential CFA was scored for primary CML (F) or normal (G) CD34+ cells. CFE values are means ± SEM of data normalized for the respective vehicle-treated control. ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001; to reduce figure cluttering, non-significant differences are not indicated.(H) Effects of MEK5/ERK5 inhibitors on primary CD11b+ CML cells. Patient-derived cells were incubated in normoxia and treated with DMSO (Vehicle), 10 μM XMD8-92 (XMD), 10 μM BIX02189 (BIX), or 1 μM imatinib (IM) from time 0 to day 3. The percentages of CD11b-expressing cells were measured by flow cytometry. Data are means ± SD of data from three patients; ^∗∗∗^p \< 0.001 versus time 0 (t0).

The effects of pharmacological inhibition of ERK5 were also tested *in vivo* using mice transplanted with BCR/ABL-transduced cells ([@bib39], [@bib47]). CML mice were treated twice daily with XMD8-92 (50 mg/kg) or placebo for 7 days starting 1 week after transplantation. Fluorescence-activated cell sorter analysis showed that the numbers of GFP+ (*BCR/ABL-*expressing; [Figures 3](#fig3){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}B), but not GFP− (*BCR/ABL-*negative; [Figure 3](#fig3){ref-type="fig"}C and data not shown) and myeloid (Gr-1+) cells decreased significantly in BM and peripheral blood (PB) of XMD8-92-treated mice compared with the placebo group. Viable cell numbers in BM ([Figure 3](#fig3){ref-type="fig"}C) and PB (not shown) of XMD8-92-treated mice did not decrease significantly when compared with the placebo-treated group, in keeping with the lack of a general toxicity of XMD8-92 ([@bib66], [@bib52], [@bib3]).

We then tested the effects of ERK5 pathway inhibition on CD34+ BMMCs from CML patients. A 2-day treatment with XMD8-92 or BIX02189 in low oxygen reduced the number of viable CD34+ cells markedly and similarly to imatinib. Importantly, XMD8-92 or BIX02189 did not affect the viability of normal CD34+ peripheral blood mononuclear cells (PBMCs) incubated in low oxygen ([Figure 3](#fig3){ref-type="fig"}D). XMD8-92 and BIX02189 decreased CFA of CD34+ CML cells in a concentration-dependent manner ([Figure 3](#fig3){ref-type="fig"}E). Importantly, 1 and 3 μM concentrations of XMD8-92 and BIX02189 were effective on cells from CML patients, but not from healthy donors ([Figures 3](#fig3){ref-type="fig"}E, [S4](#mmc1){ref-type="supplementary-material"}C, and S4D). Furthermore, XMD8-92 and BIX02189 dose-dependently reduced CFA of CFU-GEMM (colony-forming unit granulocyte, erythroid, monocyte, macrophage) and BFU-E (burst-forming unit erythroid), the progenitor cells with wider differentiation potential, from CML patients ([Figure 3](#fig3){ref-type="fig"}F). Effects on CFU-GM (colony-forming unit granulocyte macrophage) were observed only with the highest concentration of either drug. These effects matched those of imatinib. By contrast, XMD8-92 or BIX02189 showed no effect on CFA of CFU-GEMM from normal CD34+ PBMCs, with appreciable effects on BFU-E and, at the highest doses, on CFU-GM ([Figure 3](#fig3){ref-type="fig"}G). [Figure 3](#fig3){ref-type="fig"}H shows that XMD8-92 and BIX02189 prevented the decrease of CD11b+ cells occurring along a 3-day incubation in culture with respect to time 0, confirming that ERK5 pathway inhibitors are more effective on primitive rather than differentiated cells. These results are in keeping with a previous report indicating that ERK5 pathway inhibition increases the number of CD11b-positive cells in myeloid cell lines ([@bib61]). Taken together, these data indicated that pharmacological inhibition of MEK5/ERK5 reduced the overall cell number and CFA of primary CML cells, affecting in particular the more immature progenitors, and the number of CML cells *in vivo*.

Pharmacological Inhibition of the ERK5 Pathway Reduces Progenitor and Stem Cell Potential of Primary CML Cells {#sec2.4}
--------------------------------------------------------------------------------------------------------------

We first tested the effects of MEK5/ERK5 inhibitors on the maintenance of progenitor cell potential of primary CML cells. [Figure 4](#fig4){ref-type="fig"}A shows that XMD8-92 suppressed the CRA of primary cells from eight out of nine (except no. 24) CML patients, including one BC patient (no. 4), matching what shown in [Figure 2](#fig2){ref-type="fig"}A for CML cell lines. Importantly, the ERK5 inhibitor JWG-045, exhibiting lower off-target effects than XMD8-92 ([@bib64]), suppressed the progenitor cell potential of primary CML cells ([Figure 4](#fig4){ref-type="fig"}A, no. 34). CRA was also markedly inhibited or suppressed by BIX02189 (nos. 26, 29, and 34), but largely insensitive to imatinib (nos. 18, 26, 29, and 34) or dasatinib (nos. 26 and 29), in agreement with the well-known insensitivity of LSCs to TKi ([@bib25], [@bib22], [@bib24], [@bib5], [@bib31], [@bib12]). Of relevance in view of a possible translational use of these drugs, 10 μM XMD8-92 or BIX02189 did not affect the CRA of normal CD34+ PBMCs ([Figure 4](#fig4){ref-type="fig"}B). Thus, the highest concentration tested (10 μM) of either drug, despite its effectiveness on normal CD34+ PBMCs in a colony assay (CFA, [Figure 3](#fig3){ref-type="fig"}E), was ineffective in a short-term repopulation ability assay (CRA, [Figure 4](#fig4){ref-type="fig"}B), pointing to a specific role of ERK5 in the maintenance of CML, but not normal, progenitor cell potential. The effects of pharmacological inhibition of the ERK5 pathway on this potential of primary CML cells were then confirmed by serial CFA assay. Both XMD8-92 and BIX02189 suppressed CFA upon serial replating of total ([Figure 4](#fig4){ref-type="fig"}C) or CD34+ ([Figure 4](#fig4){ref-type="fig"}D) BMMCs from CML patients. MEK5/ERK5 inhibitors strongly reduced CFA starting from the primary cultures and throughout subsequent passages. Imatinib, on the contrary, exhibited partial (nos. 27 and 25) or no (nos. 28 and 35) effects on CFA of secondary and tertiary cultures. Imatinib exhibited indeed a fading-off effect while progressing with passages, showing a paradoxical stimulatory effect in the case of patient no. 35. This is in keeping with the notion that imatinib gets progressively less effective with the increase of the hierarchical level of progenitor. We then tested the effects of MEK5/ERK5 inhibitors on a longer-term repopulation ability than that detectable by CRA assays ([@bib49], [@bib18]), using the long-term culture-initiating cell (LTC-IC) assay. We confirmed the marked efficacy of these inhibitors, but not imatinib, in reducing the stem cell potential of primary CML cells but not that of normal PBMCs ([Figure 4](#fig4){ref-type="fig"}E). Finally, MEK5/ERK5 inhibitors, but not imatinib, strikingly reduced the percentage of CML BMMCs expressing CD26, a specific LSC marker in CML ([@bib29], [@bib13]) ([Figure 4](#fig4){ref-type="fig"}F). In conclusion, using several different *in vitro* assays, we showed that ERK5 pathway inhibitors were capable to target progenitor and stem CML cells.Figure 4Effects of Pharmacological Inhibition of the ERK5 Pathway on the Stem Cell Potential of Primary CML Cells(A and B) Effects of MEK5/ERK5 inhibitors on CRA of primary CML and normal CD34+ cells. Kinetics of repopulation of drug-free normoxic LC2 established with CML BMMCs (A) or normal CD34+ PBMCs (B) that had been previously incubated in 0.1% O~2~ for 7 days in LC1 while left untreated or treated with DMSO (Vehicle) or the indicated inhibitors. Data represent results from single experiments (no. 24; no. 26, Exp1: means ± SD from triplicates). BC, blast crisis; CP, chronic phase.(C and D) Effects of MEK5/ERK5 inhibitors on serial CFA of primary CML cells. Total (C) or CD34+ (D) BMMCs from CML patients were treated with DMSO (Vehicle) or the indicated inhibitors from time 0 of incubation in passage I culture. Cells were washed to remove drugs and replated weekly (II--III) and colonies scored on day 7 after each passage. Values are means ± SD of data, normalized for the respective vehicle-treated control, from single experiments performed in duplicate; ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001; ns, not significant; CP, chronic phase.(E) Effects of MEK5/ERK5 inhibitors on primary CML and normal LTC-ICs. CML BMMCs or normal PBMCs were incubated in 0.1% O~2~ for 48 hr in LC1 treated with DMSO (Vehicle) or the indicated inhibitors and transferred to drug-free normoxic LC2. After 5 weeks, LC2 cells were replated and colony number was scored after 14 days. Values are means ± SD of data from one experiment performed in duplicate and are expressed as a fraction of the value obtained for vehicle-treated culture. ^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001; ns, not significant; CP, chronic phase.(F) Effects of MEK5/ERK5 inhibitors on CD26+ CML BMMCs. Cells were incubated in normoxia for 3 days and left untreated or treated with DMSO (Vehicle), 1 μM imatinib (IM), 10 μM XMD8-92 (XMD), or 10 μM BIX02189 (BIX) from time 0. The percentages of CD26+/CD34+-expressing cells were determined by flow cytometry. Data are means ± SD of data from three patients; ^∗∗^p ≤ 0.01 versus vehicle.

Imatinib Does Not Impair the Effects of XMD8-92 in Reducing CML Cell Growth and Progenitor Cell Potential {#sec2.5}
---------------------------------------------------------------------------------------------------------

In view of a possible therapeutic use of ERK5 pathway inhibitors, it was necessary to evaluate if XMD8-92 maintained the capacity to suppress CML progenitor cell potential when combined with the standard TKi treatment ([Figure 5](#fig5){ref-type="fig"}). The XMD8-92/imatinib combination in low oxygen for 7 days was more effective than either drug alone in reducing the number of viable KCL22 and K562 cells in culture ([Figure 5](#fig5){ref-type="fig"}A). More importantly, XMD8-92 completely suppressed progenitor cell potential, regardless of the presence or the absence of imatinib in LC1 ([Figure 5](#fig5){ref-type="fig"}B). Identical results were obtained using primary CML cells ([Figure 5](#fig5){ref-type="fig"}C).Figure 5Effects of the XMD8-92/Imatinib Combination on CML Cell Lines and Primary Cells(A) Effects of XMD8-92/imatinib combination on the number of viable CML cells. KCL22 or K562 cells were incubated in 0.1% O~2~ and treated with DMSO (Vehicle), XMD8-92 (10 μM), imatinib (1 μM), or their combination (XMD + IM) from time 0 and viable cells counted at the indicated times. Values are means ± SD of data from three independent experiments; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.(B and C) Effects of XMD8-92 alone or in combination with imatinib on CRA of CML cells. Repopulation of drug-free normoxic LC2 by KCL22 or K562 (B) or patient-derived (C) CML cells that had been previously incubated in 0.1% O~2~ for 7 days in LC1 treated as in (A). Values are means ± SD of data from three independent experiments (B) or from single experiments (C). CP, chronic phase. (B) Differences between XMD8-92- or imatinib/XMD8-92-treated cultures were significant (p ≤ 0.05) from day 5 (versus vehicle-treated) or day 7 (versus imatinib-treated) on (KCL22). Differences between XMD8-92 or imatinib/XMD8-92 with respect to vehicle- or imatinib-treated cultures were significant (p ≤ 0.05) from day 14 on (K562).

The Combination of ERK5 Pathway Inhibitors with Imatinib Decreases the Expression of Stem Cell-Related Proteins {#sec2.6}
---------------------------------------------------------------------------------------------------------------

We then determined the effects of ERK5 pathway inhibitors on the expression of p21 and p27, two ERK5-regulated proteins ([@bib51], [@bib52], [@bib59], [@bib48]) that are known to regulate the normal and neoplastic HSC compartments ([@bib60], [@bib6]). Following a 7-day incubation in low oxygen, ERK5 inhibition resulted in p27 upregulation ([Figure 6](#fig6){ref-type="fig"}A), similarly to that observed at day 3 ([Figure 1](#fig1){ref-type="fig"}E). Imatinib administration determined similar effects, as reported previously ([@bib26]). On the other hand, p21 expression was not increased upon ERK5 inhibition, indicating that p21 is not regulated by ERK5 in CML cells under these experimental conditions. The combination of XMD8-92 with imatinib suppressed both p27 and p21 proteins. This combination also decreased the expression of the stemness-related genes c-MYC, SOX2, and NANOG ([@bib37], [@bib55]), but not that of OCT3/4 and KLF4, in comparison with either treatment alone or vehicle ([Figure S6](#mmc1){ref-type="supplementary-material"} and not shown).Figure 6Effects of the Combination of MEK5/ERK5 Inhibitors with Imatinib on the Expression of Stem Cell-Related Proteins(A) Cells were incubated in 0.1% O~2~ and treated with DMSO, 1 μM imatinib, 10 μM XMD8-92 (XMD), or their combination from time 0 to day 7. Cells were then lysed and immunoblotting performed; tubulin is a loading control; representative images from three independent experiments.(B) KCL22 cells were incubated in 0.1% O~2~ and treated with DMSO (Vehicle), 10 μM XMD8-92 (XMD), 10 μM BIX02189 (BIX), 1 μM imatinib (IM), or their combination (XMD + IM; BIX + IM) for 7 days. Percentages of CD26+ cells were measured by flow cytometry. Dot plots from one representative experiment including means ± SD (left) and histograms relative to CD26 mean fluorescence intensity values from three independent experiments (mean ± SD, right) are shown; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.

Finally, the combination of XMD8-92 or BIX02189 with imatinib was significantly more effective than single treatments in reducing the percentages and mean fluorescence intensity values of cells expressing the CML stem cell marker CD26 in KCL22 cells incubated in low oxygen for 7 days ([Figure 6](#fig6){ref-type="fig"}B). These experiments could not be performed with K562 cells because these cells do not express CD26 (not shown). On the whole, these results indicated that combined ERK5 pathway and BCR/ABL inhibition was more effective than single treatments in reducing the expression of stem cell-related proteins.

Discussion {#sec3}
==========

This study shows that small-molecule inhibitors targeting the ERK5 pathway almost suppressed progenitor/stem cells within CML patient-derived cells and cell lines. This conclusion was reached using several functional assays, including CRA, serial CFA, and LTC-IC, the latter assay being capable of revealing HSCs of the highest hierarchical level detectable *in vitro* ([@bib49], [@bib18]). This report identifies ERK5 pathway inhibition as a way to target LSCs, those of CML in particular.

With respect to the effects of ERK5 pathway inhibition on the overall cell population of CML lines, we found that the reduction of the number of viable cells occurred through a cytostatic rather than cytotoxic effect. The observed block of cell cycle in G0/G1 phase was similar to that described for other cell types ([@bib52], [@bib48], [@bib33]) and can be explained by the increase of p27 expression ([@bib51], [@bib52], [@bib48]). The fact that the ERK5 pathway seems to be necessary for the proliferation but not survival of CML cells is in keeping with data reported for other cell types ([@bib40], [@bib41]).

Referring to the overall primary CML cell population, XMD8-92 or BIX02189 reduced the number of viable cells incubated in low oxygen as well as CFA. The reduction of viable cells was, at least in part, due to apoptosis. Although we did not deepen the mechanisms involved in the triggering of apoptosis upon ERK5 inhibition, it would be interesting to investigate the possible role of nuclear factor κB, which has been reported to be inhibited by XMD8-92 and to collaborate in enhancing sensitivity of K562 cells to imatinib ([@bib62]). The occurrence of measurable apoptosis in primary cells upon ERK5 pathway inhibitors seems to exclude an induction of quiescence, which may be responsible for the inefficacy of TKi on LSCs ([@bib25]). Furthermore, ERK5/MEK5 inhibition determined a reduction of viable cell number and CFA of CML CD34+ cells but not cell viability or at a lower extent (CFA) of normal CD34+ cells. Noteworthy, different effects of MEK5/ERK5 inhibition on CML versus normal cells were also observed with respect to the suppression of CML progenitor/stem cell potential as determined by CRA or LTC-IC assays. Along this line, XMD8-92 reduced the number of leukemic CML cells *in vivo*, in either PB or BM, with no effect on non-leukemic cells. Altogether, these data point to a good potential therapeutic index of ERK5 pathway inhibitors on the more immature CML cell subsets.

The most important finding of this work was that MEK5/ERK5 activity is necessary for the maintenance of CML progenitor and stem cells. This conclusion was reached first using CML cell lines, which we previously demonstrated to comprise cell subsets endowed with progenitor cell potential ([@bib22], [@bib23], [@bib24]). Data were then confirmed using primary cells derived from a number of CML patients. To evaluate the effects of drugs on progenitor cell potential, we incubated CML cells in low oxygen, a condition typical of BM sites where normal HSCs are selectively maintained ([@bib46], [@bib19]), and CML cell growth but not LSC maintenance is reduced ([@bib22], [@bib23], [@bib24]). Using this strategy, it was possible to demonstrate with CML cell lines and primary cells that XMD8-92 or BIX02189 almost suppressed progenitor/stem cell potential, as determined by a number of functional assays, as well as CD34+/CD26+ cells. Imatinib, by contrast, was largely ineffective, in keeping with BCR/ABL protein suppression in low oxygen. Our results therefore indicate that ERK5 is necessary for the maintenance of BCR/ABL-independent/TKi-insensitive LSCs.

The overlapping results obtained using the ERK5 inhibitor XMD8-92 or the MEK5 inhibitor BIX02189 strengthened each other in underscoring the importance of the MEK5-ERK5 axis in CML. Furthermore, this seems to indicate that MEK5 is the main ERK5 activator in CML cells and alternative ERK5 activators are unlikely involved ([@bib15], [@bib30]). Finally, a direct involvement of ERK5 in the maintenance of CML progenitor cell potential was confirmed in K562 cells using ERK5-specific shRNA. The involvement of ERK5 pathway in stem cell biology has been recently reported for embryonic and mesenchymal stem cells ([@bib64], [@bib36], [@bib63]). Our work now provides a link between ERK5 pathway and LSC maintenance.

Another important outcome of this study is that the combination of MEK5 or ERK5 inhibitors with TKi emerged as a treatment of high potential therapeutic value. Indeed, the combination XMD8-92/imatinib was more effective than either drug alone in the debulking of CML cell lines. These results are in keeping with a previous report showing that ERK5 expression and activity are partially BCR/ABL-dependent and that the combination of imatinib treatment with ERK5 genetic suppression was more effective than imatinib alone in reducing the survival of CML cell lines ([@bib2]). Our results further support that ERK5 signaling is either dependent on or independent of BCR/ABL. More importantly, the combination with imatinib did not interfere with the suppressive effect of XMD8-92 on progenitor cell potential in CML cell lines and primary CML cells. Rather, this combination may provide advantages, as the XMD8-92/imatinib combination, differently from the single treatments, reduced the expression of stemness-related genes such as c-MYC, SOX2, and NANOG ([@bib39], [@bib37], [@bib55]), and suppressed both p21 and p27 proteins. With respect to the latter effects, p21 is critical for preventing HSC and LSC exhaustion while p27 regulates the proliferation and pool size of hematopoietic progenitor cells ([@bib7]). We therefore may speculate that, in the absence of both p21 and p27, the stem and progenitor cell compartments would be exhausted following drug-induced stress. Furthermore, while the involvement of p21 in ERK5-mediated regulation of the stem cell compartment seems to be excluded, the observed increase of p27 protein upon ERK5 pathway inhibition may prevent LSC self-renewal, as proposed for normal HSCs, and therefore reduce the size of the CML stem cell compartment ([@bib65]). The combined ERK5 pathway and BCR/ABL inhibition was also capable to target imatinib-insensitive cells expressing CD26, an LSC marker in CML ([@bib29], [@bib13]). Taken together, the above results pointed to an excellent complementarity of TKi with ERK5 pathway inhibitors in view of a possible therapeutic use of the latter.

In conclusion, ERK5 pathway inhibition appeared capable to target CML progenitor and stem cells as well as, especially in combination with TKi, the overall CML cell population, thus representing a promising strategy to prevent relapse of the disease and to contribute to TKi-driven induction of remission.

Experimental Procedures {#sec4}
=======================

Cells and Culture Conditions {#sec4.1}
----------------------------

KCL22, K562, and LAMA-84 ([@bib35], [@bib42], [@bib1]) BCR/ABL-positive CML cell lines were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, 50 U/mL penicillin, and 50 mg/mL streptomycin (all from Euro-Clone, Paignton, UK) and incubated at 37°C in a water-saturated atmosphere containing 95% air (21% O~2~) and 5% CO~2~ (referred to as "normoxia"). Cell lines were routinely tested for mycoplasma contamination and BCR/ABL expression and yearly profiled (Promega PowerPlex Fusion System kit; BMR Genomics, Padova, Italy). Cultures were renewed every 2 to 3 months by thawing a new batch of cells.

Patient-derived CML cells (see [Table 1](#tbl1){ref-type="table"} for patient characteristics) and healthy donor cells were collected following informed consent and under approval of the Ethical Committee of AOUC (authorization no. 520/10, October 18, 2010, renewed with no. 2015/0032965, November 4, 2015). MCs from BM of CML patients or PB of healthy donors were isolated by Ficoll-Hypaque gradient (Cedarlane Laboratories, ON, Canada). CML BMMCs and normal PBMCs were cultured in IMDM supplemented with 20% FBS, 2 mM glutamine, 50 U/mL penicillin, 50 mg/mL streptomycin, and, in LC1, 50 ng/mL Flt-3 ligand (no. 300-19), 20 ng/mL TPo (no. 300-18), 50 ng/mL stem cell factor (SCF) (no. 300-07), 10 ng/mL interleukin-3 (IL-3) (no. 200-03), or, in LC2, 50 ng/mL SCF, 100 ng/mL G-CSF (no. 300-23), 20 ng/mL IL-6 (no. 200-06), and 10 ng/mL IL-3 (PeproTech, Rocky Hill, NJ, USA). CD34+ cells were obtained from Ficoll-isolated BMMCs or PBMCs using CD34 MicroBead Kit (no. 130-046-703, MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) following the manufacturer\'s protocol. CD34+ enrichment was verified by flow cytometry. Experiments were performed with exponentially growing cells (3 × 10^5^/mL) incubated in normoxia or 95% N~2~, 5% CO~2~, and 0.1% O~2~ (low oxygen) in a DG250 Anaerobic Workstation (Don Whitley Scientific, Shipley, Bridgend, UK).Table 1Patients\' CharacteristicsPatient IDAge at DiagnosisCML PhaseSokal Risk*BCR*/*ABL* TranscriptELN Criteria Response445BCNANDnon-responder[a](#tblfn1){ref-type="table-fn"}561CP[b](#tblfn2){ref-type="table-fn"}highb3a2 (p210)optimal response to Dasa959ECPlowb3a2 (p210)optimal response to IM1046LCPlowb3a2 (p210)failure to IM, Dasa, Nil[c](#tblfn3){ref-type="table-fn"}1628ECPlowb2a3 (p210)optimal response to IM1754ECPlowb2a2 (p210)optimal response to Nil1866ECPintermediateNDoptimal response to Dasa2461LCPintermediateb3a2 (p210)\
e1a2 (p190)optimal response to IM2529LCPintermediateb3a2 (p210)failure to Bos; response to Dasa[c](#tblfn3){ref-type="table-fn"}2657ECPintermediateb2a2 (p210)\
e1a2 (p190)optimal response to IM2866ECPlowb2a2 (p210)optimal response to IM2978LCPlowNDsub-optimal response to IM3240ECPlowb3a2 (p210)\
b2a2 (p210)optimal response to Dasa3447ECPintermediateNDsub-optimal response to Nil3560ECPlowb2a2 (p210)optimal response to Dasa3655ECPintermediateb3a2 (p210)optimal response to Nil3760ECPintermediateb3a2 (p210)optimal response to IM3874ECPintermediateb3a2 (p210)optimal response to IM3969ECPintermediateb3a2 (p210)optimal response to Dasa4072ECPintermediateb3a2 (p210)NA (too short therapy follow up)4142ECPintermediateb3a2 (p210)NA (too short therapy follow up)4260ECPintermediateb3a2 (p210)NA (too short therapy follow up)4351ECPlowb3a2 (p210)NA (too short therapy follow up)4577ECPintermediateb3a2 (p210)NA (too short therapy follow up)4675ECPlowb3a2 (p210)optimal response to IM[^2][^3][^4][^5]

Drugs {#sec4.2}
-----

ERK5 inhibitors XMD8-92 ([@bib66]) and JWG-045 ([@bib64]) (Gray\'s laboratory and MedChemexpress LLC, Princeton, NJ, USA); MEK5 inhibitor BIX02189 ([@bib58]) (MedChemexpress LLC); imatinib (no. 202180, Santa Cruz, Biotechnology, Dallas, TX, USA); dasatinib (no. 1586, Biovision, Milpitas, CA, USA). All drugs were dissolved in DMSO.

Kinase Assay {#sec4.3}
------------

Kinase activity of endogenous ERK5 was measured using a non-radioactive ERK Assay Kit (no. 17--191, Merck Millipore, Billerica, MA, USA) following the manufacturer's instructions. The ability of immunoprecipitated ERK5 to phosphorylate myelin basic protein was evaluated by western blotting.

Measurement of Cell Viability, Apoptosis, and Cell-Cycle Phases {#sec4.4}
---------------------------------------------------------------

Cell viability was measured by trypan blue exclusion test and IC~50~ values were calculated using GraphPad Prism software (La Jolla, CA, USA). Apoptosis (Annexin-V-FLUOS Staining Kit, no. 11988549001, Roche Diagnostics, Basel, Switzerland) and cell-cycle phase distribution (propidium iodide staining) were estimated by flow cytometry using a FACSCanto (Beckton Dickinson, San Josè, CA, USA) as reported previously ([@bib52]).

CRA Assay {#sec4.5}
---------

The CRA assay is an *in vitro* substitute for the MRA assay *in vivo* where the estimate of the overall progenitor cell potential (short-term repopulation ability) is obtained via cell transfer to liquid cultures (LC2) to monitor the entity and kinetics of their repopulation ([@bib22], [@bib23], [@bib32], [@bib10], [@bib11]). Cells (3 × 10^5^ cells/mL) were incubated for 7 days in low oxygen (LC1) while being subjected to drug treatment (a full dose at time 0 and a half dose on day 3). Cells were then washed free of drug and transferred (3 × 10^4^ cells/mL) to normoxic LC2, where kinetics of viable cell number was measured, reflecting the CRA of LC1 cells. Culture medium was never changed during LC1 or LC2.

LTC-IC Assay {#sec4.6}
------------

BMMCs from CML patients or normal CD34+ PBMCs (1 × 10^6^/mL) were drug-treated for 48 hr in low oxygen, resuspended in Myelocult (no. 05100, Stem Cell Technology, Vancouver, BC, Canada) supplemented with hydrocortisone (10^−6^ M), seeded (BMMCs from CML patients 2 × 10^6^/35-mm dish; normal CD34+ PBMC 5 × 10^3^/35-mm dish) onto a feeder layer of irradiated (8,000 cGy) murine stromal cells (M2-10B4 cell line) and incubated in normoxia. Half medium was replaced weekly. After 5 weeks, cells were recovered, counted, and replated (5 × 10^4^ cells/35-mm dish) in methylcellulose-containing medium (no. 04435, Stem Cell Technology) ([@bib57]). Colonies were scored after 14 days of incubation.

CFA Assay {#sec4.7}
---------

CFA and serial CFA were performed as recently reported ([@bib5]). Number and type of colonies were scored after 7 days. When serial CFA assay was performed, colony cells recovered from day 7 cultures were washed to remove drugs, replated (1 × 10^5^/35-mm dish) in methylcellulose-containing medium and incubated for 7 days. Colony formation efficiency was calculated dividing the number of colonies scored by the number of plated cells.

Cell Lysis and Western Blotting {#sec4.8}
-------------------------------

Total cell lysates and western blotting were performed as described previously ([@bib51]). Antibodies used are listed in [Table S1](#mmc1){ref-type="supplementary-material"}.

RNA Interference by Lentiviral Vectors {#sec4.9}
--------------------------------------

Stable knockdown of ERK5 in K562 cells was performed using lentiviral vectors carrying shRNA specific for ERK5 ([Table S2](#mmc1){ref-type="supplementary-material"}), as described previously ([@bib52]).

Mice {#sec4.10}
----

C57BL/6J-CD45.1 mice (The Jackson Laboratory, Bar Harbor, ME, USA) were handled in accordance with protocols and regulations approved by the IACUC of University of Massachusetts Medical School. CML mice were treated twice daily with XMD8-92 (50 mg/kg) or placebo (30% 2-hydroxypropyl-β-cyclodextrin), via intraperitoneal injection, for 7 days starting from day 7 after BM transplantation.

Murine CML Model {#sec4.11}
----------------

Retroviruses were prepared and CML induced in mice as described previously ([@bib5], [@bib39], [@bib47]). Donor mice were injected with 5-FU (200 mg/kg; no. 6627, Sigma-Aldrich) via tail vein and sacrificed after 4 days. BM cells were flushed out of femurs and tibiae, infected with the above viruses, counted and transplanted (5 × 10^5^ cells in 300 μL/mouse) into recipient mice pre-treated with two doses of 550 cGy gamma 2 hr apart from each other.

Flow Cytometry {#sec4.12}
--------------

Intact or permeabilized (0.5% Tween 20) cells were incubated with primary ([Table S1](#mmc1){ref-type="supplementary-material"}) and then fluorescence *in situ* hybridization- or allophycocyanin-conjugated secondary antibodies (Chemicon International, Temecula, CA, USA). Background signal was determined using matched isotype control. 7AAD (no. 559925, BD Biosciences, San Josè, CA, USA)-negative cells were considered for analysis.

Statistical Analysis {#sec4.13}
--------------------

Data represent means ± SEM or ± SD of values obtained in at least three independent experiments; p values were calculated using Student\'s t test or one-way ANOVA (when more than two samples were compared).
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[^1]: Co-senior author

[^2]: ECP, early chronic phase (CP); LCP, late CP; BC, blast crisis; ELN, European Leukemia Net (2013); Bos, bosutinib; Dasa, dasatinib; IM, imatinib; Nil, nilotinib; NA, not applicable; ND, not done.

[^3]: As expected on the basis of diagnosis (BC).

[^4]: Relapse post allogeneic transplant.

[^5]: BCR/ABL mutations not found.
